Fish Consumption Linked With Better Survival Outcomes in Colon Cancer

Video

This video examines the results of a prospective study that looked at associations between survival outcomes and fish and omega-3 fatty acid intake among colon cancer patients.

In this video, Erin Van Blarigan, ScD, of the University of California, San Francisco, discusses the results of a prospective study that looked at associations between survival outcomes and fish and long-chain omega-3 fatty acid intake after a colon cancer diagnosis.

The study included 1,011 stage III colon cancer patients who were part of an adjuvant chemotherapy trial, and found that patients who consumed dark meat fish at least twice per month had longer recurrence-free survival (hazard ratio [HR], 0.61; 0.44–0.83; P = .005), disease-free survival (HR, 0.64; 0.48–0.86; P = .007), and overall survival (HR, 0.68; 0.48–0.97; P = .05) compared with those who consumed no fish. The study also found that in patients with COX2 tumor expression, long-chain omega-3 fatty acid was associated with improved disease-free survival.

Results of the study (abstract 585) were presented last month at the 2017 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco.

Related Videos
Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.
Laparoscopy may reduce the degree of pain or length of hospital stay compared with open surgery for patients with colorectal cancer.
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
The toxicity profile of tislelizumab also appears to look better compared with chemotherapy in metastatic esophageal squamous cell carcinoma.